OptimizeRx (OPRX)
(Delayed Data from NSDQ)
$9.35 USD
-0.18 (-1.89%)
Updated Apr 18, 2024 04:00 PM ET
After-Market: $9.35 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth A Momentum B VGM
Balance Sheet
Fiscal Year End for OptimizeRx Corp falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 14 | 74 | 85 | 11 | 19 |
Receivables | 37 | 22 | 25 | 18 | 7 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | 3 | 2 | 6 | 4 | 1 |
Total Current Assets | 54 | 99 | 115 | 33 | 27 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | 128 | 36 | 25 | 27 | 29 |
Deposits & Other Assets | 1 | 0 | 0 | 0 | 0 |
Total Assets | 183 | 135 | 141 | 60 | 57 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | 2 | 2 | 1 | 1 | 0 |
Current Portion Long-Term Debt | 2 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | 8 | 3 | 3 | 2 | 2 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | 6 | 4 | 6 | 7 | 4 |
Total Current Liabilities | 18 | 8 | 9 | 10 | 6 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 4 | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | 34 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | 5 |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | 57 | 9 | 10 | 10 | 12 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 191 | 173 | 167 | 86 | 78 |
Retained Earnings | -64 | -47 | -35 | -36 | -33 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 127 | 126 | 131 | 50 | 45 |
Total Liabilities & Shareholder's Equity | 183 | 135 | 141 | 60 | 57 |
Total Common Equity | 100,126 | 126 | 131 | 50 | 45 |
Shares Outstanding | 18.15 | 17.15 | 17.70 | 15.10 | 14.10 |
Book Value Per Share | 5,516.56 | 7.35 | 7.42 | 3.31 | 3.18 |
Fiscal Year End for OptimizeRx Corp falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | -99,985 | 64 | 63 | 74 |
Receivables | NA | 37 | 21 | 18 | 18 |
Notes Receivable | NA | NA | 0 | 0 | 0 |
Inventories | NA | NA | 0 | 0 | 0 |
Other Current Assets | NA | 3 | 3 | 4 | 4 |
Total Current Assets | NA | 54 | 87 | 85 | 96 |
Net Property & Equipment | NA | 0 | 0 | 0 | 0 |
Investments & Advances | NA | NA | 0 | 0 | 0 |
Other Non-Current Assets | NA | NA | 0 | 0 | 0 |
Deferred Charges | NA | NA | 0 | 0 | 0 |
Intangibles | NA | 128 | 35 | 36 | 35 |
Deposits & Other Assets | NA | 1 | 1 | 0 | 0 |
Total Assets | NA | 183 | 124 | 121 | 132 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | NA | 0 | 0 | 0 |
Accounts Payable | NA | 2 | 1 | 1 | 3 |
Current Portion Long-Term Debt | NA | 2 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | NA | 0 | 0 | 0 |
Accrued Expenses | NA | 8 | 3 | 2 | 0 |
Income Taxes Payable | NA | NA | 0 | 0 | 0 |
Other Current Liabilities | NA | 6 | 4 | 3 | 4 |
Total Current Liabilities | NA | 18 | 8 | 6 | 8 |
Mortgages | NA | NA | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 4 | 0 | 0 | 0 |
Convertible Debt | NA | NA | 0 | 0 | 0 |
Long-Term Debt | NA | 34 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | NA | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | NA | 0 | 0 | 0 |
Total Liabilities | NA | 57 | 8 | 6 | 8 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | NA | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 191 | 176 | 173 | 177 |
Retained Earnings | NA | -64 | -60 | -57 | -53 |
Other Equity | NA | NA | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 127 | 116 | 116 | 124 |
Total Liabilities & Shareholder's Equity | NA | 183 | 124 | 121 | 132 |
Total Common Equity | 0 | 100,126 | 116 | 116 | 124 |
Shares Outstanding | 18.15 | 18.15 | 16.60 | 17.10 | 17.10 |
Book Value Per Share | 0.00 | 5,516.56 | 6.99 | 6.77 | 7.25 |